Hyphen Pharma - SAC Capital 2023-05-25: Beyond The Shores

• Hyphens Pharma (SGX:1J5), established in 1998, is Singapore’s leading specialty pharmaceutical and consumer healthcare group with a diverse footprint in ASEAN countries.
• Hyphens Pharma holds exclusive licenses and main distributorship with top pharmaceutical companies globally, mainly from Europe and the United States. They also build a strong franchise by means of in-licensing and R&D collaborations with reputable research institutions in Singapore.
• - Read this at SGinvestors.io -
• - Read this at SGinvestors.io -
• Hyphens Pharma products are selling in the premium market while Novem are targeting mostly the public sector. Prior to Novem acquisition, ~42% of sales are from the government. With the Healthier SG scheme, the public sector will grow at a faster pace, benefitting the Hyphens Pharma from the acquisition where ~60% of Novem sales are to government hospitals and polyclinics.

Hyphens Pharma – Investment Thesis

Internationalization

• Read more at SGinvestors.io.

Read also SAC's most recent report:
2025-03-10 Hyphens Pharma International - Strong Growth Momentum.

Previous report by SAC:
2024-08-22 Hyphens Pharma International - Commendable Growth Amid Economic Headwinds.

Price targets by other brokers at Hyphens Pharma Target Prices.

Listing of research reports at Hyphens Pharma Analyst Reports.

Relevant links:
Hyphens Pharma Share Price History,
Hyphens Pharma Announcements,
Hyphens Pharma Dividend Payout Dates & Corporate Actions,
Hyphens Pharma News